In a report published Tuesday, Oppenheimer analysts initiated coverage on La Jolla Pharmaceutical Co. (LJPC) with an ‘Outperform‘ rating and $43 price target. On valuation measures, La Jolla Pharmaceutical Co. shares currently have a PEG ratio of (0.66). EPS for the same period is ($2.00). Currently there are 3 analysts that rate LJPC a ‘Buy’. […]
View the full post at: Notable Initiations: La Jolla Pharmaceutical (LJPC), SolarCity (SCTY), HubSpot (HUBS), Geron (GERN), Lumber Liquidators (LL)